Demonstrates that the VeraBIND Tau assay accurately measures active tau pathology—a key biomarker of Alzheimer’s disease (AD) and other tauopathies—in individuals with and without cognitive impairment.
July 28, 2025
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Demonstrates that the VeraBIND Tau assay accurately measures active tau pathology—a key biomarker of Alzheimer’s disease (AD) and other tauopathies—in individuals with and without cognitive impairment.